🔗 Share this article

While America proceeds with sweeping revisions to its vaccine guidelines, an unexpected name appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccinations during the global health crisis and has focused upon alleged deaths following Covid immunization in her short tenure at the Food and Drug Administration.

Planned Overhauls to Childhood Vaccine Schedule

Health officials were set to unveil sweeping revisions to the pediatric vaccination calendar in December, synchronizing the US with the Danish national calendar, according to reports – a major change that would put the US out of step with many the global community with no evidence for improved outcomes. The announcement has been postponed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is set to address the audience at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to head the center this calendar year.

A New Direction at the Agency

The acting appointment might represent a closer partnership between the drug and biologics centers as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has often pushed for ending specific childhood vaccine recommendations in the US in order to be more similar to the Danish model, a society with universal health coverage and a population roughly the population of the state of Wisconsin.

To date statements, she has kept her attention on vaccines – usually the domain of Dr. Prasad, chief of the FDA’s CBER – instead of drug regulation.

Doubts Over Background

Høeg has no apparent track record in medication creation, approval processes or management, which has been typical for past leaders of the CBER. She has served at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“She appears not to have the necessary background” for leading the drug-regulation department, said Jonathan Howard. “She lacks experience running a scientific study. She is not versed in leading a large organization. She has no expertise in industry regulation.”

Former commissioners of CBER would “be deeply familiar with legal statutes and the science of medication creation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that previous people who ran CBER have had.”

CDER has an enormous portfolio at the FDA, Woodcock emphasized.

“Everybody just pays attention on the new drug program, but the generic program authorizes thousands of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and other areas, and all of those need to be managed,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership aspect to the job, which supervises over 5,000 staff members. “It’s a massive management job, if you do it right,” Woodcock said.

Response and Controversial Programs

In response to inquiries about Høeg’s credentials and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a spokesperson responded that the “concerns stem from inaccurate presumptions”.

“This background matches the duties of her job,” the official explained, noting the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's recently launched priority voucher program, a contentious one-day medication authorization process that reportedly troubled her predecessors. “How are these drugs being chosen for this expedited pathway? Who is making the choices?” Dr. Howard asked. “There’s a lot of secrecy going on at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards less stringent regulations of most medications, except for immunizations.”

Public Track Record on Immunizations

Concerning immunizations, Høeg has a clearer, if problematic, history, critics observe. She authored a study using unverified crowd-sourced reports to assess the incidence of heart inflammation after COVID-19 vaccination. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to imply Covid vaccines are pose a greater threat than they are.

Included in her “wish list” for the current government featured changing rules for new vaccines and ending “non-essential” vaccines, she remarked post-election on a audio program. At the agency, Høeg has allegedly proposed barring young men from receiving COVID-19 vaccines.

“She is an all-around true believer who begins with her preconceived notions and tailors the evidence to retrofit the science in a highly deceptive, fraudulent way,” Dr. Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|